CTP-221 is the deutered enhanced drug for lenalidomide, or commercial drug known as Revlimid, which is manufactued by Celgene. The drug targets indications in Myelodysplastic Syndrome (MDS) and Multiple Myeloma amongst others, and is expected to produce revenue up to seven billion annually for the company. This is the second Celgene drug after CTP-730 that Concert may consider for clinical trials. The patent for Revlimid runs through 2026. CTP-221 has shown to be approximately 5-6 fold greater potency in animal models with similar antitumor effects. Thank you for reading.
No comments:
Post a Comment